Invivyd, Inc. has made significant progress in the development and commercialization of monoclonal antibody ("mAb") therapies for the prevention and treatment of serious viral infectious diseases, with a primary focus on combating COVID-19. The company's first mAb, PEMGARDA, received emergency use authorization ("EUA") from the U.S. Food and Drug Administration ("FDA") in March 2024 for the pre-exposure prophylaxis of COVID-19 in immunocompromised individuals.
The company has also made strides in the development of a next-generation mAb candidate, VYD2311, for COVID-19. In September 2024, Invivyd announced the dosing of the first participants in a Phase 1/2 clinical trial of VYD2311, and in June 2025, positive full Phase 1/2 clinical data for VYD2311 for both safety and pharmacokinetics were reported. Furthermore, the company has received alignment with advice from the FDA on a rapid pathway to potential Biologics License Application ("BLA") approval for VYD2311 for the prevention of COVID-19.
The company has also initiated the DECLARATION Phase 3 clinical trial to evaluate VYD2311's safety and efficacy in the prevention of symptomatic, RT-PCR-confirmed COVID-19, with top-line data anticipated in mid-2026. Additionally, the FDA has granted "Fast Track" designation for VYD2311 for the prevention of COVID-19 in individuals with underlying risk factors for progression to severe disease.
In addition to its COVID-19 programs, Invivyd has announced the selection of VBY329, a potential best-in-class mAb candidate being developed for the prevention of respiratory syncytial virus (RSV) infections in neonates, infants, and children. The company also continues to investigate additional mAbs for the treatment and prevention of other important infectious diseases, such as measles.
Invivyd has financed its operations primarily through the sale and issuance of preferred and common stock, including net proceeds from its initial public offering ("IPO") and sales of its product, PEMGARDA. However, the company has incurred significant losses, including a net loss of $52.5 million for the year ended December 31, 2025, and as of that date, it had an accumulated deficit of $954.5 million.
The company's ability to achieve profitability is heavily dependent on the successful development and commercialization of its product candidates. It anticipates the need for additional funding through a combination of contribution from revenues, equity offerings, government or private-party grants, debt financings, or other capital sources to support its continuing operations and pursue its growth strategy.
Based on current operating plans and excluding any contribution from future revenues or external financing, Invivyd may not have sufficient cash and cash equivalents to fund its operating expenses and capital requirements beyond one year from the issuance date of the consolidated financial statements in its Annual Report on Form 10-K, leading to substantial doubt about its ability to continue as a going concern.
In terms of financial performance, the company's product revenue, net, primarily from the sales of PEMGARDA in the U.S., has contributed to its income. However, the cost of product revenue and the significant expenses associated with research and development, clinical trials, manufacturing, and commercialization efforts have resulted in substantial losses and significant expenses.
Invivyd's future success and financial stability are contingent upon the successful development and commercialization of its product candidates, as well as its ability to secure additional funding. However, the company's inability to achieve profitability or secure additional funding could lead to a reduction or termination of its operations.
Invivyd's financial statements and related notes, as well as the "Risk Factors" section of its Annual Report on Form 10-K, provide further details on its financial condition and results of operations. The market has reacted to these announcements by moving the company's shares 0.41% to a price of $2.45. For the full picture, make sure to review Invivyd's 10-K report.
